1. Home
  2. RVNC

RVNC

Revance Therapeutics Inc.

Logo Revance Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.

Founded: 1999 Country:
United States
United States
Employees: N/A City: NASHVILLE
Market Cap: 397.1M IPO Year: 2014
Target Price: $14.00 AVG Volume (30 days): 1.8M
Analyst Decision: Buy Number of Analysts: 9
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -3.83 EPS Growth: N/A
52 Week Low/High: $4.10 - $37.98 Next Earning Date: 05-07-2024
Revenue: $234,040,000 Revenue Growth: 76.55%
Revenue Growth (this year): 22.78% Revenue Growth (next year): 35.79%

Share on Social Networks: